跳至主要内容
临床试验/NCT01420510
NCT01420510Unknown2 期

Saginil in Vaginal Cannulas vs. Placebo for the Prevention of Vaginitis in Gynecologic Oncologic Patients Receiving Chemotherapy: a Randomized Controlled Trial.

Università degli Studi dell'Insubria1 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2011年9月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
发起方
入组人数
60
试验地点
1
主要终点
Number of patients with vaginitis in the group taking Adelmidrol (vaginal cannulas) vs. number of patients with vaginitis in the Placebo group

研究概览

简要总结

We hypothesise that the use of Adelmidrol (Saginil in vaginal cannulas) can reduce the incidence and magnitude of vaginitis in patients affected by gynecologic malignancies.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

性别
Female
接受健康志愿者

入选标准

  • Gynecologic malignancy
  • Current administration of chemotherapy

排除标准

  • Colpectomy
  • Vaginal cancer
  • Vulvar cancer
  • Bacterial vaginitis

研究组 & 干预措施

Adelmidrol

Experimental

Efficacy of Adelmidrol vaginal gel in preventing vaginitis in oncologic patients

干预措施: Adelmidrol vaginal gel (Drug)

Placebo

Placebo Comparator

Efficacy of Placebo in preventing vaginitis in oncologic patients

干预措施: Placebo vaginal gel (Drug)

结局指标

主要结局

Number of patients with vaginitis in the group taking Adelmidrol (vaginal cannulas) vs. number of patients with vaginitis in the Placebo group

时间窗: 2 months

次要结局

未报告次要终点

研究者

发起方
Università degli Studi dell'Insubria
申办方类型
Other
责任方
Principal Investigator
主要研究者

Fabio Ghezzi

Professor

Università degli Studi dell'Insubria

研究点 (1)

Loading locations...

相似试验